Tag: Takeda Pharmaceutical

Takeda’s TAK-279 meets primary endpoint in Phase 2b trial for psoriatic arthritis

businessnewstoday- September 12, 2023

Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2 inhibitor for treating psoriatic arthritis. Meeting its ... Read More

Takeda’s TAK-755 shows potential in Phase 3 trial for cTTP prophylaxis

businessnewstoday- June 25, 2023

Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant ADAMTS13 protein in development for the prophylactic ... Read More

Takeda’s HYQVIA reduces CIDP relapse rates, Phase 3 trial reveals

businessnewstoday- June 22, 2023

Takeda Pharmaceutical Company has disclosed successful outcomes from its critical Phase 3 ADVANCE-CIDP 1 trial, focused on evaluating HYQVIA as a maintenance therapy for adults ... Read More

Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China

Raghuram Kadari- January 24, 2023

Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More

Takeda gets QDENGA EC approval as dengue vaccine

Raghuram Kadari- December 12, 2022

Takeda has received the European Commission’s (EC) marketing authorization for the company’s dengue vaccine QDENGA (Dengue Tetravalent Vaccine ) (TAK-003). The QDENGA vaccine is indicated ... Read More

Strides Pharma Science gets FDA approval for Colchicine Tablets generic

pallavi123- March 13, 2022

Strides Pharma Science Limited said that its Singapore-based stepdown fully-owned subsidiary — Strides Pharma Global Pte. Limited has secured approval for Colchicine Tablets USP, 0.6 ... Read More

Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial

pharmanewsdaily- September 11, 2020

Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed ... Read More

Takeda to sell select non-core assets to Cheplapharm for $562m

pharmanewsdaily- September 9, 2020

Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm ... Read More

Takeda to divest consumer healthcare business to Blackstone for $2.3bn

pharmanewsdaily- August 24, 2020

Japanese pharma giant Takeda Pharmaceutical has agreed to sell its consumer healthcare business to Oscar A-Co KK, a company controlled by funds managed by The ... Read More

Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan

pharmanewsdaily- August 8, 2020

US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former's COVID‑19 vaccine candidate, in Japan. ... Read More